Azilva Ranks No. 1 Both in GP, HP Market in May: Rep Track Survey

According to Anterio Inc.’s Rep Track Survey, which investigates the recollections of doctors of drug detailing activities, Takeda Pharmaceutical’s novel angiotensin receptor blocker (ARB) Azilva (azilsartan), which was launched at the end of May, ranked first both in the GP...read more